Xilio Therapeutics (XLO) Other Operating Expenses (2020)

Xilio Therapeutics' (XLO) quarterly Other Operating Expenses came in at $37.9 million in Q4 2020.

Xilio Therapeutics (XLO) Other Operating Expenses (2020) Analysis & Trends

Xilio Therapeutics has disclosed Other Operating Expenses across 1 years of filings, most recently posting $37.9 million for Q4 2020.

Other Operating Expenses for Q4 2020 came in at $37.9 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $37.9 million (changed N/A YoY), and the FY2020 annual result was $37.9 million, changed N/A from the prior year.
Other Operating Expenses came in at $37.9 million for Q4 2020 at Xilio Therapeutics.
In the past five years, Other Operating Expenses ranged from a high of $37.9 million in Q4 2020 to a low of $37.9 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Xilio Therapeutics	144.35 Mn	-5.95 Mn	-

Download Data

Date	Value
Dec 31, 2020	37.91 Mn